Repurposing mefloquine for pancreatic cancer treatment
Treatments studied
This trial tests whether adding the malaria drug mefloquine to standard chemotherapy can help treat pancreatic cancer. It may make the chemotherapy more effective for people whose cancer cannot be removed by surgery or has spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have pancreatic cancer that cannot be surgically removed or has spread to other parts of the body.
- You are about to start standard chemotherapy (either FOLFIRINOX or gemcitabine/nab-paclitaxel), or you have already tried standard treatments without success and are otherwise not eligible for them.
- You are willing to receive your cancer care at UF Health for at least the next 3 months.
- Your liver and kidney function must be within acceptable limits, and you must have adequate blood cell counts.
- You must not have a history of seizures, epilepsy, or certain psychiatric conditions (like psychosis or major depression).
- You must be able to swallow oral medications and not have any condition that affects your stomach or intestines' ability to absorb the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs—a standard chemotherapy called FOLFIRINOX and an investigational drug called pentamidine—in people with advanced pancreatic cancer. The goal is to see if this combination is safe and effective, and it may slow tumor growth.
This trial tests a new medicine (FG-M108) combined with chemotherapy for pancreatic cancer that is advanced or has spread. The medicine targets a protein found on some pancreatic cancer cells, and the goal is to see if it helps shrink tumors or slow the cancer more than chemotherapy alone.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
This trial studies giving chemo and hydroxychloroquine before surgery for resectable pancreatic cancer. The goal is to shrink the tumor and improve the chances of successful removal.
This trial tests combining a fecal microbiota transplant (FMT, a procedure to restore healthy gut bacteria) with an investigational immunotherapy (SHR-1701) and standard chemotherapy drugs (nab-paclitaxel and gemcitabine) as first treatment for advanced pancreatic cancer. The goal is to see if this combination slows tumor growth and helps you live longer.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.